" class="no-js "lang="en-US"> Vistin Pharma Enters into a Long-term Renewable Energy Supply Agreement with Statkraft - Medtech Alert
Monday, October 02, 2023

Vistin Pharma Enters into a Long-term Renewable Energy Supply Agreement with Statkraft

Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) announces that it has entered into a long-term industrial energy agreement with Statkraft, the leading Norwegian energy supplier. The agreement will secure a significant part of Vistin’s electricity demand on competitive terms until 2032. The agreement includes Guarantees of Origin as certification of the renewable energy supply, and starts 1.1.2023.

2022 has been very challenging for Vistin and the Norwegian industry, when it comes to electricity costs, with extreme volatility and record-high electricity prices in the NO2 area where Vistin’s fully automated production plant is located.

“This agreement will give Vistin Pharma stable electricity supply at predictable and competitive prices. The agreement helps to secure our competitiveness in the global Metformin market. We are happy that Statkraft by this agreement contributes to the future development of Vistin and thereby allows the company to continue focusing on its growth strategy,” says Kjell-Erik Nordby, CEO in Vistin Pharma.

“We are very pleased to conclude another renewable energy contract with the Norwegian industry which confirms that Statkraft offers relevant solutions at competitive terms,” says Frode Berntsen, Head of Industry Nordics & Baltics at Statkraft.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more